Glucocorticoid-induced adrenal insufficiency after receiving intravenous methylprednisolone for Graves' ophthalmopathy: a case report
Main Article Content
Abstract
BACKGROUND
Graves’ ophthalmopathy (GO) is the most common extrathyroidal manifestation of Graves’ disease and can significantly impair visual function and quality of life. High-dose intravenous methylprednisolone (IVMP) is recommended as first-line therapy for moderate-to-severe active GO due to its superior efficacy and tolerability compared with oral glucocorticoids. However, IVMP therapy may be associated with rare but potentially serious adverse effects, including suppression of the hypothalamic–pituitary–adrenal (HPA) axis leading to GI adrenal insufficiency (GI-AI).
Case description
We report the case of a 38-year-old man with Graves’ disease who developed AI following IVMP therapy for moderate-to-severe GO. The patient received five weekly doses of IVMP 500 mg (cumulative dose 2.5 g) for progressive ocular symptoms. He subsequently presented with fatigue, weight gain, moon face, and buffalo hump. Laboratory evaluation revealed a markedly low morning serum cortisol level of 1 mcg/dL, confirming adrenal insufficiency. Patient was diagnosed with GI-AI accompanied by features of iatrogenic Cushing’s syndrome. Management consisted of hydrocortisone replacement therapy at a dose of 20 mg/day along with ongoing antithyroid treatment using methimazole. Serial monitoring of cortisol levels demonstrated gradual recovery of HPA axis function, accompanied by clinical improvement.
Conclusion
This case highlights that glucocorticoid-induced adrenal insufficiency can occur on IVMP used for GO. Clinicians should maintain a high index of suspicion and perform appropriate adrenal function monitoring during and after IVMP therapy to ensure early detection and safe management of this potentially life-threatening complication.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
1. Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid 2022;32:1439-70. doi: 10.1089/thy.2022.0251.
2. Subekti I, Soewondo P, Soebardi S, et al. Practical guidelines management of Graves ophthalmopathy. Acta Med Indones 2019;51:364-71.
3. Kulbay M, Tanya SM, Tuli N, et al. A comprehensive review of thyroid eye disease pathogenesis: from immune dysregulations to novel diagnostic and therapeutic approaches. Int J Mol Sci 2024;25:11628. doi: 10.3390/ijms252111628.
4. Li X, Li S, Fan W, et al. Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review. Int Ophthalmol 2023;43:1437-49. doi:10.1007/s10792-022-02537-6.
5. Hoang TD, Stocker DJ, Chou EL, Burch HB. 2022 Update on clinical management of Graves disease and thyroid eye disease. Endocrinol Metab Clin North Am 2022;51:287-304. doi:10.1016/j.ecl.2021.12.004.
6. Bello OM, Druce M, Ansari E. Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review. BMJ Open Ophthalmol 2024;9:e001515. doi: 10.1136/bmjophth-2023-001515.
7. Jespersen S, Nygaard B, Kristensen LØ. Methylprednisolone pulse treatment of Graves’ ophthalmopathy is not associated with secondary adrenocortical insufficiency. Eur Thyroid J 2015;4:222-5. doi:10.1159/000440834.
8. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:2171-80. doi:10.1210/jc.2015-1218.
9. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol 2015;3:216-26. doi:10.1016/S2213-8587(14)70142-1.
10. Ambroziak U, Bluszcz G, Bednarczuk T, Miśkiewicz P. The influence of Graves’ orbitopathy treatment with intravenous glucocorticoids on adrenal function. Endokrynologia Polska 2017;68:430–3. DOI: 10.5603/EP.a2017.0036.
11. Pelewicz K, Szewczyk S, Miśkiewicz P. Treatment with intravenous methylprednisolone in patients with Graves' orbitopathy significantly affects adrenal function: assessment of serum, salivary cortisol and serum dehydroepiandrosterone sulfate. J Clin Med 2020;9:3233. doi: 10.3390/jcm9103233.
12. Pelewicz K, Miśkiewicz P. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test. J Endocrinol Invest 2024;47:1987-94. doi:10.1007/s40618-024-02304-7.
13. Pelewicz K, Miśkiewicz P. Glucocorticoid withdrawal—an overview on when and how to diagnose adrenal insufficiency in clinical practice. Diagnostics (Basel) 2021;11:728. doi: 10.3390/diagnostics11040728.
14. Nachawi N, Li D, Lansang MC. Glucocorticoid-induced adrenal insufficiency and glucocorticoid withdrawal syndrome: two sides of the same coin. Cleve Clin J Med 2024;91245-55. doi:10.3949/ccjm.91a.23039.
15. Längericht J, Krämer I, Kahaly GJ. Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab 2020;11:2042018820958335. doi: 10.1177/2042018820958335.